Dr. Sacks is a co-author on four poster presentations at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes Research) being held in Boston May 7-10. Three of these presentations report analyses of healthcare resource use, costs to payers, and mortality in rare and ultra-rare diseases (adrenomyelonueropathy [AMN] and non-cystic fibrosis bronchiectasis [NCFB]). Another looks at healthcare resource use and costs associated with oral antibiotic treatment failure in patients treated for uncomplicated urinary tract infection (UTI) in the US. If you are at ISPOR, reach out to Naomi!
Author Archives: cmccormick
Scientists from EpidStrategies are attending ISPOR 2023 in Boston!
Scientists from EpidStrategies are attending ISPOR 2023 in Boston! Please reach out and connect with us and meet the newest addition to our team, HEOR expert Naomi Sacks.
EpidStrategies Researchers Are Presenting at the 2023 Pediatric Academic Societies Meeting
EpidStrategies, a division of ToxStrategies LLC, is excited to announce that Mina Suh, Naimisha Movva, Xiaohui Jiang, Sue Pastula, and Heidi Reichert, along with Eric Simoes from University of Colorado, will present “The Burden of RSV and Bronchiolitis in the US Infant Medicaid Population Extends Beyond the Inpatient Setting” on Sunday April 30th, 3:00 pm EST, at the 2023 Pediatric Academic Societies (PAS) Meeting in Washington, DC.
This is a birth cohort study of United States Medicaid infants, which evaluated 2016–2018 state-level data for respiratory syncytial virus (RSV) across all health-care settings. These data offer the opportunity to describe health trends and outcomes associated with RSV in this disenfranchised group and to explore issues of health equity.
Our team, along with colleagues in industry and academia, have been engaged in ongoing research on RSV and bronchiolitis since 2016. In addition to the work being presented at 2023 PAS, our team has presented abstracts at ReSViNET (2023), American Academy of Pediatrics (2021; 2020), International Conference on Pharmacoepidemiology & Therapeutic Risk Management (2021), 2021 PAS, and IDWeek 2020 and has recently published manuscripts in the Journal of Infectious Diseases (2022), Therapeutic Advances in Infectious Disease (2022), and the Journal of Pediatrics (2021), describing the morbidity and mortality burden of RSV among US infants and children under age 5 years.
EpidStrategies is committed to guiding and supporting clients in understanding the epidemiology of infectious diseases and developing therapies. We have extensive experience managing and conducting systematic literature reviews and primary and secondary data analyses examining a range of exposures and outcomes. Please contact Mina Suh at msuh@epidstrategies.com if you would like to hear more about our work and how we can help you achieve project goals. Learn more about EpidStrategies at https://epidstrategies.com/.